Pacer Advisors
NRIX icon

Pacer Advisors’s Nurix Therapeutics NRIX Stock Holding History

Pacer Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28K Buy
+1,142
New +$19.5K ﹤0.01% 2184
2024
Q3 		– Sell
-781
Closed -$16.3K – 2643
2024
Q2 		$16.3K Sell
781
-204
-21% -$3.18K ﹤0.01% 3466
2024
Q1 		$14.5K Buy
+985
New +$10.6K ﹤0.01% 3489
2021
Q2 		– Sell
-1,581
Closed -$49K – 1499
2021
Q1 		$49K Buy
1,581
+1,042
+193% +$39.4K ﹤0.01% 1440
2020
Q4 		$18K Buy
+539
New +$17.9K ﹤0.01% 1488

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pacer Advisors's NRIX Position: Q2 2026 in Review

Pacer Advisors opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 1,142 shares worth $28K. The stake represents ﹤0.01% of the portfolio and ranks #2184 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in NRIX as recently as Q2 2024.

Pacer Advisors first reported a position in NRIX in Q4 2020 and has held it in 5 quarters since. The position peaked at $49K in Q1 2021. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Pacer Advisors held 1,142 shares of Nurix Therapeutics worth $28K as of Q2 2026.
  • Nurix Therapeutics was a new Pacer Advisors position in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2184 holding.
  • Pacer Advisors first reported a position in Nurix Therapeutics in Q4 2020 and has held it in 5 quarters since.
  • Pacer Advisors's Nurix Therapeutics position peaked at $49K in Q1 2021.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.